Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept phase II study of sorafenib in resectable hepatocellular carcinoma
2009-018058-44Phase 2Active
- Sponsor
- GERCOR
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by GERCOR. Primary endpoints: pathological changes and anti-tumor activity. Started Mar 2010; status: active.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-018058-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018058-44.